Abstract
Measuring the adaptive immune response to SARS-CoV-2 can enable the assessment of past infection as well as protective immunity and the risk of reinfection. While neutralizing antibody (nAb) titers are one measure of protection, such assays are challenging to perform at a large scale and the longevity of the SARS-CoV-2 nAb response is not fully understood. Here, we apply a T-cell receptor (TCR) sequencing assay that can be performed on a small volume standard blood sample to assess the adaptive T-cell response to SARS-CoV-2 infection. Samples were collected from a cohort of 302 individuals recovered from COVID-19 up to 6 months after infection. Previously published findings in this cohort showed that two commercially available SARS-CoV-2 serologic assays correlate well with nAb testing. We demonstrate that the magnitude of the SARS-CoV-2-specific T-cell response strongly correlates with nAb titer, as well as clinical indicators of disease severity including hospitalization, fever, or difficulty breathing. While the depth and breadth of the T-cell response declines during convalescence, the T-cell signal remains well above background with high sensitivity up to at least 6 months following initial infection. Compared to serology tests detecting binding antibodies to SARS-CoV-2 spike and nucleoprotein, the overall sensitivity of the TCR-based assay across the entire cohort and all timepoints was approximately 5% greater for identifying prior SARS-CoV-2 infection. Notably, the improved performance of T-cell testing compared to serology was most apparent in recovered individuals who were not hospitalized and were sampled beyond 150 days of their initial illness, suggesting that antibody testing may have reduced sensitivity in individuals who experienced less severe COVID-19 illness and at later timepoints. Finally, T-cell testing was able to identify SARS-CoV-2 infection in 68% (55/81) of convalescent samples having nAb titers below the lower limit of detection, as well as 37% (13/35) of samples testing negative by all three antibody assays. These results demonstrate the utility of a TCR-based assay as a scalable, reliable measure of past SARS-CoV-2 infection across a spectrum of disease severity. Additionally, the TCR repertoire may be useful as a surrogate for protective immunity with additive clinical value beyond serologic or nAb testing methods.
Competing Interest Statement
R.E., T.M.S., R.M.G., and I.M.K. declare employment and equity ownership with Adaptive Biotechnologies. S.C.D. declares employment and equity ownership with Adaptive Biotechnologies and employment with Stanford University School of Medicine. A.W. declares institutional support from NIH. A.G. declares consulting fees with Abbott; institutional support from Abbott, Merck, and Gilead; and family employment at Labcorp. H.J.Z. and J.M.C. declare employment and equity ownership with Microsoft Corporation. T.M., L.B., and H.S.R. declare leadership, employment, and equity ownership with Adaptive Biotechnologies. D.M.K. declares institutional support from NIAID Contract 75N93019C00063. J.B., S.S., M.H.W., C.M., and M.R.H. declare no conflicts of interest.
Clinical Trial
T-cell repertoire profiles and antigen annotation data from the multiplexed antigen-stimulation experiments will be available as part of the ImmuneCODE data resource (Nolan 2020), and can be downloaded from the Adaptive Biotechnologies immuneACCESS site under the immuneACCESS Terms of Use at https://clients.adaptivebiotech.com/pub/covid-2020.
Funding Statement
Supported by Adaptive Biotechnologies. The project was funded in part by the Frederick National Laboratory for Cancer Research with support from the National Institute for Allergy and Infectious Diseases (NIAID) contract 75N91019D00024. This work was also supported by the Fred Hutchinson Joel Meyers Endowment (J.B.), Fast-Grants (J.B.), a new investigator award from the American Society for Transplantation and Cell Therapy (J.B.). This work was also supported by NIH contract 75N93019C0063 (D.M.K.). Editorial support was provided by Melanie Styers of BluPrint Oncology Concepts, funded by Adaptive Biotechnologies. This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), U.S. Department of Health and Human Services (DHHS), under Contract No. HHSN272201800013C. M.R.H. performed this work as an employee of Laulima Government Solutions, LLC. The content of this publication does not necessarily reflect the views or policies of the DHHS or of the institutions and companies with which the authors are affiliated.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board approval was obtained from the University of Washington and all participants completed informed consent forms.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
T-cell repertoire profiles and antigen annotation data from the multiplexed antigen-stimulation experiments will be available as part of the ImmuneCODE data resource (Nolan 2020), and can be downloaded from the Adaptive Biotechnologies immuneACCESS site under the immuneACCESS Terms of Use at https://clients.adaptivebiotech.com/pub/covid-2020.
